Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2021 2,711 · FY2022 4,488 · FY2023 6,075 — 3-yr total 13,274
Operates in Pharma — Distribution. Per the activity note to the FY2023 annual report, the company conducts wholesale and retail trade in pharmaceutical products in specialized pharmacies.
| Line item | 2020 | 2021 | 2022 | 2023 | CAGR |
|---|---|---|---|---|---|
| 12,886 | 20,504 | 37,998 | 45,135 | +51.9% | |
| Total COGS | 6,646 | 10,361 | 19,190 | 27,931 | +61.4% |
| Gross Profit | 6,240 | 10,142 | 18,808 | 17,203 | +40.2% |
| Gross Margin | 48.4% | 49.5% | 49.5% | 38.1% | |
| Other Operating Income | 0 | 0 | 307 | 4 | -98.6% |
| 922 | 1,326 | 1,563 | 3,332 | +53.4% | |
| EBITDA | 5,318 | 8,817 | 17,552 | 13,876 | +37.7% |
| EBITDA Margin | 41.3% | 43.0% | 46.2% | 30.7% | |
| Total D&A | 0 | 120 | 231 | 373 | +76.3% |
| EBIT / Operating Income | 5,318 | 8,697 | 17,321 | 13,503 | +36.4% |
| Total Interest Expense | 119 | 33 | 8 | 18 | -46.2% |
| Total Other Income | 24 | 80 | 207 | 156 | +86.9% |
| Profit Before Tax | 5,175 | 8,744 | 17,105 | 13,328 | +37.1% |
| Total Income Tax | 0 | 414 | 792 | 1,079 | +61.4% |
| Net Profit / (Loss) | 5,175 | 8,178 | 16,313 | 12,249 | +33.3% |
| Net Margin | 40.2% | 39.9% | 42.9% | 27.1% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →